Predicting T Cell Receptor Antigen Specificity From Structural Features Derived From Homology Models of Receptor-Peptide-Major Histocompatibility Complexes

Predicting T Cell Receptor Antigen Specificity From Structural Features Derived From Homology Models of Receptor-Peptide-Major Histocompatibility Complexes post thumbnail image

The physical interaction between the T cell receptor (TCR) and its cognate antigen causes T cells to activate and participate in the immune response. Understanding this physical interaction is important in predicting TCR binding to a target epitope, as well as potential cross-reactivity. Here, we propose a way of collecting informative features of the binding interface from homology models of T cell receptor-peptide-major histocompatibility complex (TCR-pMHC) complexes.

The information collected from these structures is sufficient to discriminate binding from non-binding TCR-pMHC pairs in multiple independent datasets. The classifier is limited by the number of crystal structures available for the homology modelling and by the size of the training set. However, the classifier shows comparable performance to sequence-based classifiers requiring much larger training sets.

A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen ReceptorT Cell Therapy

Ewing’s sarcoma (EWS) is a malignant and aggressive tumor type that predominantly occurs in children and adolescents. Traditional treatments such as surgery, radiotherapy and chemotherapy, while successful in the early disease stages, are ineffective in patients with metastases and relapses who often have poor prognosis. Therefore, new treatments for EWS are needed to improve patient’s outcomes.

Chimeric antigen receptor (CAR)-T cells therapy, a novel adoptive immunotherapy, has been developing over the past few decades, and is increasingly popular in researches and treatments of various cancers. CAR-T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of leukemia and lymphoma. Recently, this therapeutic approach has been employed for solid tumors including EWS. In this review, we summarize the safety, specificity and clinical transformation of the treatment targets of EWS, and point out the directions for further research.

Autologous Transplant versus Chimeric Antigen Receptor Tcell Therapy for Relapsed DLBCL in Partial Remission

The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) versus chimeric antigen receptor T-cell (CAR-T) therapy in diffuse large B-cell lymphoma (DLBCL) patients who achieve a partial remission (PR) after salvage chemotherapy is not known. Using the Center for International Blood & Marrow Transplant Research registry database, we identified adult DLBCL patients who received either an auto-HCT (2013-2019) or CAR-T treatment with axicabtagene ciloleucel while in a PR by CT or PET scan.

We compared the clinical outcomes between the two cohorts using univariable and multivariable regression models after adjustment for relevant baseline and clinical factors. In the univariable analysis, the 2-year progression-free survival and the rate of 100-day non-relapse mortality (4% vs. 2% ; p=0.3) were not different between the 2 cohorts but consolidation with auto-HCT was associated with a lower rate of relapse/progression (40% vs. 53% ; p=0.05) and a superior overall survival (OS) at 2-years.

In the multivariable regression analysis, treatment with auto-HCT was associated with a significantly lower risk of relapse/progression rate (HR=1.49; p=0.01) and a superior OS (HR=1.63; p=0.008). In patients with DLBCL in a PR after salvage therapy, treatment with auto-HCT was associated with a lower incidence of relapse and a superior OS compared with CAR-T. These data support the role of auto-HCT as the standard-of-care in transplant-eligible patients with relapsed DLBCL in PR after salvage therapy.

Distinct single-component adjuvants steer human DC-mediated Tcell polarization via Toll-like receptor signaling toward a potent antiviral immune response

The COVID-19 pandemic highlights the importance of efficient and safe vaccine development. Vaccine adjuvants are essential to boost and tailor the immune response to the corresponding pathogen. To allow for an educated selection, we assessed the effect of different adjuvants on human monocyte-derived dendritic cells (DCs) and their ability to polarize innate and adaptive immune responses. In contrast to commonly used adjuvants, such as aluminum hydroxide, Toll-like receptor (TLR) agonists induced robust phenotypic and functional DC maturation.

In a DC-lymphocyte coculture system, we investigated the ensuing immune reactions. While monophosphoryl lipid A synthetic, a TLR4 ligand, induced checkpoint inhibitors indicative for immune exhaustion, the TLR7/8 agonist Resiquimod (R848) induced prominent type-1 interferon and interleukin 6 responses and robust CTL, B-cell, and NK-cell proliferation, which is particularly suited for antiviral immune responses.

Indeed, we could confirm that the cytokine profile induced by lipid-complexed RNA was almost identical to the pattern induced by R848. Although this awaits further investigation, our results suggest that their efficacy involves the highly efficient antiviral response pattern stimulated by the RNAs’ TLR7/8 activation.

CNS relapse of acute lymphocytic leukaemia is difficult to treat. Durable remissions of relapsed or refractory B-cell acute lymphocytic leukaemia have been observed following treatment with CD19-directed chimeric antigen receptor (CAR) T cells; however, most trials have excluded patients with active CNS disease. We aimed to assess the safety and activity of CAR T-cell therapy in patients with a history of CNS relapsed or refractory B-cell acute lymphocytic leukaemia.

In this post-hoc analysis, we included 195 patients (aged 1-29 years; 110 [56%] male and 85 [44%] female) with relapsed or refractory CD19-positive acute lymphocytic leukaemia or lymphocytic lymphoma from five clinical trials (Pedi CART19, 13BT022, ENSIGN, ELIANA, and 16CT022) done at the Children’s Hospital of Philadelphia (Philadelphia, PA, USA), in which participants received CD19-directed CAR T-cell therapy between April 17, 2012, and April 16, 2019.

The trials required control of CNS disease at enrolment and infusion and excluded treatment in the setting of acute neurological toxic effects (>grade 1 in severity) or parenchymal lesions deemed to increase the risk of neurotoxicity.The recently licensed COVID-19 vaccines, BNT162b and mRNA-1273, are both based on single-stranded RNA.

Long-term Cell Tracer 580 (Green) sample

P710GS 0.1 ml
EUR 199

Long-term Cell Tracer 580 (Yellow) sample

P710YS 0.1 ml
EUR 199

CFDA SE Cell Tracer Kit

K1023-1 1 kit
EUR 96
Description: The CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Cell Tracer Kit is usually used in fluorescence analyses as a long-term tracer of cells. The Kit can be used for in vitro and in vivo labeling of cells to determine whether or not a cell is proliferating, especially.

FluoGreen Tracer, Stains Cell Nuclei and Cytoplasm

MBS555420-01mL 0.1mL
EUR 435

FluoGreen Tracer, Stains Cell Nuclei and Cytoplasm

MBS555420-5x01mL 5x0.1mL
EUR 1815

CFDA SE cell proliferation and tracer detection kit

ETF0051 2000 assays
EUR 300

CFDA SE cell prolifeRation and tracer detection kit

MBS8579509-2000Assays 2000Assays
EUR 400

CFDA SE cell prolifeRation and tracer detection kit

MBS8579509-5x2000Assays 5x2000Assays
EUR 1810

FluoGreen Tracer

SF41000 100 ul
EUR 522

Tau tracer 1

T39660-10mg 10mg Ask for price
Description: Tau tracer 1

Tau tracer 1

T39660-1g 1g Ask for price
Description: Tau tracer 1

Tau tracer 1

T39660-1mg 1mg Ask for price
Description: Tau tracer 1

Tau tracer 1

T39660-50mg 50mg Ask for price
Description: Tau tracer 1

Tau tracer 1

T39660-5mg 5mg Ask for price
Description: Tau tracer 1

Tau tracer 2

T37051-10mg 10mg Ask for price
Description: Tau tracer 2

Tau tracer 2

T37051-1g 1g Ask for price
Description: Tau tracer 2

Tau tracer 2

T37051-1mg 1mg Ask for price
Description: Tau tracer 2

Tau tracer 2

T37051-50mg 50mg Ask for price
Description: Tau tracer 2

Tau tracer 2

T37051-5mg 5mg Ask for price
Description: Tau tracer 2

Tau tracer 2

MBS5798041-50mg 50(mg
EUR 960

Tau tracer 2

MBS5798041-5x50mg 5x50(mg
EUR 4180

Tau tracer 1

MBS5800094-5mg 5(mg
EUR 915

Tau tracer 1

MBS5800094-5x5mg 5x5(mg
EUR 3970

Tau tracer 1

HY-134879 Get quote Ask for price
Description: Tau tracer 1 is a Tau tracer used for imaging Tau protein aggregates. Tau tracer 1 can be used to diagnose neurodegenerative diseases[1].

Tau tracer 2

HY-134880 10 mg
EUR 216.45
Description: Tau tracer 2 (Pl-2620) is a Tau tracer used for imaging Tau protein aggregates. Tau tracer 2 can be used to diagnose neurodegenerative diseases[1].

JAK2 JH2 Tracer

HY-102055 50mg
EUR 5515.2

JAK2 JH2 Tracer

T19017-10mg 10mg Ask for price
Description: JAK2 JH2 Tracer

JAK2 JH2 Tracer

T19017-1g 1g Ask for price
Description: JAK2 JH2 Tracer

JAK2 JH2 Tracer

T19017-1mg 1mg Ask for price
Description: JAK2 JH2 Tracer

JAK2 JH2 Tracer

T19017-50mg 50mg Ask for price
Description: JAK2 JH2 Tracer

JAK2 JH2 Tracer

T19017-5mg 5mg Ask for price
Description: JAK2 JH2 Tracer

JAK2 JH2 Tracer

MBS3844504-10mg 10mg
EUR 855

JAK2 JH2 Tracer

MBS3844504-1mg 1mg
EUR 225

JAK2 JH2 Tracer

MBS3844504-50mg 50mg
EUR 2450

JAK2 JH2 Tracer

MBS3844504-5mg 5mg
EUR 525

JAK2 JH2 Tracer

MBS3844504-5x50mg 5x50mg
EUR 11020

JAK2 JH2 Tracer

MBS5755856-50mg 50mg
EUR 2840

JAK2 JH2 Tracer

MBS5755856-5x50mg 5x50mg
EUR 12620

ROS tracer precursor

T19550-10mg 10mg Ask for price
Description: ROS tracer precursor

ROS tracer precursor

T19550-1g 1g Ask for price
Description: ROS tracer precursor

ROS tracer precursor

T19550-1mg 1mg Ask for price
Description: ROS tracer precursor

ROS tracer precursor

T19550-50mg 50mg Ask for price
Description: ROS tracer precursor

ROS tracer precursor

T19550-5mg 5mg Ask for price
Description: ROS tracer precursor

ROS tracer precursor

MBS5772039-5mg 5mg
EUR 915

ROS tracer precursor

MBS5772039-5x5mg 5x5mg
EUR 3970

ROS tracer precursor

HY-126712 Get quote Ask for price
Description: ROS tracer precursor is the precursor of [18F]ROStrace for the synthesis of ROStrace, which can be used for disease diagnosis[1].

CytoFixâ„¢ BCECF, AM *Optimized for long term cellular pH tracking*

21200-1mg 1 mg
EUR 318
Description: Intracellular pH plays an important modulating role in many cellular events, including cell growth, calcium regulation, enzymatic activity, receptor-mediated signal transduction, ion transport, endocytosis, chemotaxis, cell adhesion and other cellular processes.

Long-Term Cell Tracing Reagent CMAC (Blue)

EGY0171 100µg
EUR 92

Long-Term Cell Tracing Reagent CMAC (Blue)

EGY0172 5x100µg
EUR 340

Long-Term Cell Tracing Reagent CMAC (Blue)

MBS8579546-01mg 0.1mg
EUR 185

Long-Term Cell Tracing Reagent CMAC (Blue)

MBS8579546-5x01mg 5x0.1mg
EUR 420

Long-Term Cell Tracing Reagent CMFDA(Green)

EGY0181 100µg
EUR 220

Long-Term Cell Tracing Reagent CMFDA(Green)

EGY0182 5x100µg
EUR 500

Long-Term Cell Tracing Reagent CMFDA (Green)

MBS8579547-01mg 0.1mg
EUR 300

Long-Term Cell Tracing Reagent CMFDA (Green)

MBS8579547-5x01mg 5x0.1mg
EUR 580

Long-Term Cell Tracing Reagent CDCFDA, SE (Green)

EGY0161 100 µg
EUR 160

Long-Term Cell Tracing Reagent CDCFDA, SE (Green)

EGY0162 5 x 100 µg
EUR 340

Long-Term Cell Tracing Reagent CDCFDA, SE (Green)

MBS8579545-01mg 0.1mg
EUR 245

Long-Term Cell Tracing Reagent CDCFDA, SE (Green)

MBS8579545-5x01mg 5x0.1mg
EUR 420

IAA tracer (alkaline phospahatase conjugated)

AS09-517 1000 assays
EUR 208

ABA tracer (alkaline phospahatase conjugated)

AS10-726 1000 assays
EUR 230

NIR-FLIVO 690 Tracer In vivo Assay

MBS258410-20Tests 20Tests
EUR 535

NIR-FLIVO 690 Tracer In vivo Assay

MBS258410-5x20Tests 5x20Tests
EUR 2460

NIR-FLIVO 747 Tracer In vivo Assay

MBS258412-20Tests 20Tests
EUR 535

NIR-FLIVO 747 Tracer In vivo Assay

MBS258412-5x20Tests 5x20Tests
EUR 2460

CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Colorimetric

CBA-135 96 assays
EUR 715

CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Colorimetric

CBA-135-5 5 x 96 assays
EUR 3095

CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Fluorometric

CBA-140 96 assays
EUR 750

CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Fluorometric

CBA-140-5 5 x 96 assays
EUR 3215

Cis-zeatin tracer (alkaline phospahatase conjugated)

AS16-4092 1000 assays
EUR 230

Trans-zeatin tracer (alkaline phospahatase conjugated)

AS16-4090 1000 assays
EUR 230

NIR-FLIVO® 690 Tracer In vivo Assay

9112 20 Tests
EUR 438

NIR-FLIVO® 747 Tracer In vivo Assay

9114 20 Tests
EUR 438

CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric, Trial Size

CBA-135-T 24 assays
EUR 518.4
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.

CytoSelect 96-Well Cell Transformation Assay (Cell Recovery Compatible, Fluorometric), Trial Size

CBA-140-T 24 assays
EUR 547.2
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.

N6-isopentenyladenosine tracer (alkaline phospahatase conjugated)

AS17-4132 1000 assays
EUR 208

CytoSelect™ 96-well Cell Transformation Assay

CBA-130 96 assays
EUR 640

CytoSelect™ 96-well Cell Transformation Assay

CBA-130-5 5 x 96 assays
EUR 2695

HRP conjugated mAb anti-Human TNF-alpha (Tracer)

MBS592166-02mL 0.2mL
EUR 580

HRP conjugated mAb anti-Human TNF-alpha (Tracer)

MBS592166-5x02mL 5x0.2mL
EUR 2355

CytoSelect 384-well Cell Transformation Assay, Fluorometric

CBA-145 384 assays
EUR 1208.4
Description: Our CytoSelect 384-Well Cell Transformation Assay uses a modified soft agar 3D matrix to support the formation of colonies by neoplastic cells. Quantitation of cell transformation is performed on a fluorescence plate reader.

CytoSelect 384-well Cell Transformation Assay, Fluorometric

CBA-145-5 5 x 384 assays
EUR 4681.2
Description: Our CytoSelect 384-Well Cell Transformation Assay uses a modified soft agar 3D matrix to support the formation of colonies by neoplastic cells. Quantitation of cell transformation is performed on a fluorescence plate reader.

Biotin conjugated mAb anti-Human TNF-alpha (Tracer)

MBS592389-01mL 0.1mL
EUR 580

Biotin conjugated mAb anti-Human TNF-alpha (Tracer)

MBS592389-5x01mL 5x0.1mL
EUR 2355

293AD Cell Line

AD-100 1 vial
EUR 365

293AAV Cell Line

AAV-100 1 vial
EUR 405

293LTV Cell Line

LTV-100 1 vial
EUR 405

293RTV Cell Line

RV-100 1 vial
EUR 405

StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible)

CBA-325 96 assays
EUR 1027.2
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis.

StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible)

CBA-325-5 5 x 96 assays
EUR 4033.2
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis.

293/GFP Cell Line

AKR-200 1 vial
EUR 460

T47D/GFP Cell Line

AKR-208 1 vial
EUR 686.4
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

A549/GFP Cell Line

AKR-209 1 vial
EUR 460

HeLa/GFP Cell Line

AKR-213 1 vial
EUR 460

293/Cas9 Cell Line

AKR-5110 1 vial
EUR 460

HeLa/Cas9 Cell Line

AKR-5111 1 vial
EUR 460

NIH3T3/GFP Cell Line

AKR-214 1 vial
EUR 460

NIH3T3/Cas9 Cell Line

AKR-5104 1 vial
EUR 460

MCF-7/Luc Cell Line

AKR-234 1 vial
EUR 686.4
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line.

SKOV-3/Luc Cell Line

AKR-232 1 vial
EUR 686.4
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line.

OVCAR-5/RFP Cell Line

AKR-254 1 vial
EUR 686.4
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line.

mAb Anti Human PD-L1 clone 12B4, Tracer (Biotin) (Monoclonal)

MBS590085-01mL 0.1mL
EUR 565

mAb Anti Human PD-L1 clone 12B4, Tracer (Biotin) (Monoclonal)

MBS590085-5x01mL 5x0.1mL
EUR 2290

CytoSelect™ 96-Well Cell Transformation Assay (Soft Agar Colony Formation), Trial Size

CBA-130-T 24 assays
EUR 320

mAb Anti-Human PD-1/CD279, 7G12, Tracer (Biotin) (Monoclonal

MBS590084-01mL 0.1mL
EUR 565

mAb Anti-Human PD-1/CD279, 7G12, Tracer (Biotin) (Monoclonal

MBS590084-5x01mL 5x0.1mL
EUR 2290

Collagen-based Cell Contraction Assay

CBA-201 24 assays
EUR 420

Radius 384-Well Cell Migration Assay

CBA-127 384 assays
EUR 721.2
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap.

Radius 384-Well Cell Migration Assay

CBA-127-5 5 x 384 wells
EUR 2802
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap.

HIF-1 Alpha Cell Based ELISA Kit

CBA-281 96 assays
EUR 734.4
Description: Cell Biolabs? HIF-1 Cell Based ELISA Kit is an immunoassay developed for rapid detection of HIF-1 Alpha in fixed cells. Cells on a microplate are stimulated for HIF-1 Alpha stabilization, fixed, permeabilized, and then neutralized in the well. HIF-1 Alpha is then detected with an anti-HIF-1 alpha antibody followed by an HRP conjugated secondary antibody. Each kit provides sufficient reagents to perform up to a total of 96 assays and can detect HIF-1 Alpha from human, mouse, or rat.

CytoSelect™ MTT Cell Proliferation Assay

CBA-252 960 assays
EUR 320

Radius™ 24-Well Cell Migration Assay

CBA-125 24 assays
EUR 425

Radius™ 24-Well Cell Migration Assay

CBA-125-5 5 x 24 assays
EUR 1820

Radius™ 96-Well Cell Migration Assay

CBA-126 96 assays
EUR 495

Radius™ 96-Well Cell Migration Assay

CBA-126-5 5 x 96 assays
EUR 2095

Radius™ 48-Well Cell Migration Assay

CBA-5037 48 assays
EUR 445

Radius™ 48-Well Cell Migration Assay

CBA-5037-5 5 x 48 assays
EUR 1895

CytoSelect Cell Proliferation Assay Reagent (Fluorometric)

CBA-250 10 mL
EUR 490.8
Description: Cell Biolabs? CytoSelect Cell Proliferation Assay Reagent (Fluorometric) provides a fluorometric format for measuring and monitoring cell proliferation. Cells can be plated and then treated with compounds or agents that affect proliferation.  Cells are then incubated with the proliferation reagent.  Upon entering metabolically active live cells, the non-fluorescent proliferation reagent is converted into a bright red fluorescent form. An increase in cell proliferation is accompanied by increased fluorescent signal, while a decrease in cell proliferation (and signal) can indicate the toxic effects of compounds or suboptimal culture conditions.  The assay principles are basic and can be applied to most eukaryotic cell lines, including adherent and non-adherent cells and certain tissues.  This cell proliferation reagent can be used to detect proliferation in bacteria, yeast, fungi, protozoa as well as cultured mammalian and piscine cells. The kit contains sufficient reagents for the evaluation of 960 assays in ten 96-well plates or 192 assays in eight 24-well plates.

CytoSelect™ BrdU Cell Proliferation ELISA Kit

CBA-251 96 assays
EUR 455

CytoSelect™ Cell Viability and Cytotoxicity Assay

CBA-240 96 assays
EUR 305

Platinum-E Retroviral Packaging Cell Line, Ecotropic

RV-101 1 vial
EUR 770

Platinum-GP Retroviral Packaging Cell Line, Pantropic

RV-103 1 vial
EUR 770

CytoSelect 24-well Laminin Cell Invasion, Colorimetric

CBA-110-LN 12 assays
EUR 714
Description: The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the morbidity and mortality of cancers. Cell invasion requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Our CytoSelect Cell Invasion Assays utilize precoated inserts to assay the invasive properties of tumor cells. Invasive cells can be quantified in 24-well plates on either a standard microplate reader or a fluorescence plate reader. Inserts are precoated on the top of the membrane with Laminin.

Platinum-A Retroviral Packaging Cell Line, Amphotropic

RV-102 1 vial
EUR 770

CytoSelect™ 24-Well Cell Co-Culture System

CBA-160 24 assays
EUR 365

CytoSelect™ 24-Well Cell Co-Culture System

CBA-160-5 5 x 24 assays
EUR 1585

154 patients from Pedi CART19, ELIANA, ENSIGN, and 16CT022 received tisagenlecleucel and 41 patients from the 13BT022 trial received the humanised CD19-directed CAR, huCART19. We categorised patients into two strata on the basis of CNS status at relapse or within the 12 months preceding CAR T-cell infusion-either CNS-positive or CNS-negative disease. Patients with CNS-positive disease were further divided on the basis of morphological bone marrow involvement-either combined bone marrow and CNS involvement, or isolated CNS involvement.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post